A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

Part of paid clinical trials in Basking Ridge, New Jersey.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT06698003
Phase
PHASE2
Status
Recruiting

Conditions

  • Lymphoma
  • T-Cell Leukemia/Lymphoma, Adult
  • T-cell Leukemia
  • T-cell Leukemia/Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Mogamulizumab — DRUG
    Cohort 1: 0.3 mg/kg of mogamulizumab every 12 weeks, for 2 total doses Cohort 2: 0.3 mg/kg of mogamulizumab every 6 weeks, for 4 total doses

Study Details

The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because they are infected with the HTLV-1 virus and because of changes seen in some of their immune system cells called T-cells.

Key Dates

Start date
Nov 15, 2024
Status verified
Mar 2026
Primary completion
Nov 15, 2029
Completion
Nov 15, 2029

Study Design

Enrollment
134 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1
    Cohort 1: 0.3 mg/kg of mogamulizumab every 12 weeks, for 2 total doses
  • Experimental: Cohort 2
    Cohort 2: 0.3 mg/kg of mogamulizumab every 6 weeks, for 4 total doses

Primary Outcome Measure

Minimum dose and schedule of mogamulizumab to reduce the proviral load by ≥75% [ Time Frame: 6 months from baseline ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering at Basking Ridge (All protocol activities)Basking RidgeNew Jersey07920
Steven Horwitz, MD
646-608-2680
Memorial Sloan Kettering Monmouth (All protocol activities)MiddletownNew Jersey07748
Steven Horwitz, MD
646-608-2680
Memorial Sloan Kettering Bergen (All Protocol Activities)MontvaleNew Jersey07645
Steven Horwitz, MD
646-608-2680
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities)CommackNew York11725
Steven Horwitz, MD
646-608-2680
Memorial Sloan Kettering Westchester (All protocol activities)HarrisonNew York10604
Steven Horwitz, MD
646-608-2680
Memorial Sloan Kettering Cancer Center (All Protocol Activities)New YorkNew York10065
Steven Horwitz, MD
646-608-2680
Memorial Sloan Kettering Nassau (All protocol activities)UniondaleNew York11553
Steven Horwitz, MD
646-608-2680

Find similar trials in Basking Ridge, NJ

Related Studies